- Home
- LUCY vs CYCN Comparison
LUCY vs CYCN Comparison
Compare LUCY & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | CYCN |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 7.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | LUCY | CYCN |
|---|---|---|
| Price | $1.15 | $1.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 217.1K | ★ 4.2M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,392,547.00 | ★ $2,855,000.00 |
| Revenue This Year | $80.76 | N/A |
| Revenue Next Year | $210.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 53.22 | ★ 1371.65 |
| 52 Week Low | $0.95 | $1.16 |
| 52 Week High | $7.08 | $6.25 |
Technical Indicators
Market Signals| Indicator | LUCY | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 69.99 |
| Support Level | $1.36 | $1.16 |
| Resistance Level | $1.17 | $1.51 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 39.58 | 79.46 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.